FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Ocaliva Confirmatory Trial Fails: FDA

FDA asks members of its Gastrointestinal Drugs Advisory Committee whether they believe that the benefits of using Intercepts Ocaliva to treat some cas...

latest-news-card-1
Biologics

GSK Nixes Herpes Simplex Virus Vaccine

GSK decides to not advance the development of an investigational herpes simplex virus vaccine candidate based on data from a recent Phase 1-2 study.

Medical Devices

Hinge Health Wireless Pain Device Cleared

FDA clears a Hinge Health 510(k) for its Enso 3, a wireless device for reducing musculoskeletal pain.

latest-news-card-1
Human Drugs

CGMP Violations at Zydus Lifesciences Facility

FDA warns Zydus Lifesciences Limited about CGMP violations in its production of finished drugs.

latest-news-card-1
Medical Devices

Multiple Optikem International Violations Cited

FDA warns Denver, CO-based Optikem International about Quality System Regulation and other violations in its production of ophthalmic solutions.

latest-news-card-1

Changes Sought in FDA Misinformation Guidance

Three trade groups representing companies regulated by FDA recommend changes to a draft guidance on addressing misinformation about prescription drugs...

Medical Devices

FDA Clears Sonic Incytes Velacur Device

FDA clears Sonic Incytes Velacur Determined Fat Fraction measuring tool.

latest-news-card-1
Federal Register

Priority Voucher Used on Incytes Opzelura

Federal Register notice: FDA announces that it approved Incytes Opzelura (ruxolitinib) using a rare pediatric disease priority review voucher.

latest-news-card-1
Human Drugs

FDA Mulls More Post-Inspection Feedback: Cavazzoni

CDER director Patrizia Cavazzoni tells a drug regulatory conference that FDA is considering more opportunities for sponsors to learn about inspection ...

latest-news-card-1

Follow FDA Online Misinformation Guidance: Attorneys

Two Cooley attorneys urge companies regulated by FDA to follow the guidelines in a 7/8 draft guidance on responding to misinformation carried on the I...